Biotechnology
PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT
SYDNEY, June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II, genomically-guided study of multiple therapies in patients with brain metastases, led by the Alliance for Clinical Trials in Oncology (NC...
2022-06-07 19:00
1528
Molecular Stethoscope, Inc. announces new investment from the Alzheimer's Drug Discovery Foundation
Investment by the ADDF will accelerate the translation of Molecular Stethoscope's cf-mRNA liquid biopsy technology platform into products and services for the diagnosis and management of Alzheimer's disease SOUTH SAN FRANCISCO, Calif., June 7, 2022 /PRNewswire/ -- Molecular Stethoscope, a leadin...
2022-06-07 18:00
1479
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-...
2022-06-07 14:00
1859
Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting
KANAGAWA, Japan, June 7, 2022 /PRNewswire/ -- Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today announced that it has presented the interim results from the Phase 1 clinical trial of CTX-712, a selective pan-CDC-...
2022-06-07 14:00
1515
SCG Cell Therapy And A*STAR's IMCB Collaborate To Accelerate Clinical Translation of Immune Cell-based Therapy
* The collaboration agreement works toward accelerating the study of SCG's immunotherapy pipeline and candidates such as CAR-T, TCR-T therapies, antibodies, and vaccines. * SCG will contribute its proprietary technologies to the therapeutic development of immune cell-based therapy candidates....
2022-06-07 12:23
2646
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018
– Discovered in-house by the internal R&D Team at Antengene, ATG-018 is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathway. – This Phase I study will evaluate the safety, pharmacology and prelim...
2022-06-07 11:34
2312
Pharmactive Enters Strategic Partnership with Nutraconnect for APAC
Pharmactive targets Asia Pacific Market with new collaboration
MADRID, June 7, 2022 /PRNewswire/ -- Pharmactive Biotech Products
2022-06-07 09:00
1992
iNtRON Completes GLP-TOX Studies of BAL200
* A novel drug candidate for anthrax received orphan drug designation (ODD) by the US FDA. BOSTON and SEOUL, Korea, June 6, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200. The co...
2022-06-07 09:00
1866
Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory
NEW YORK, June 6, 2022 /PRNewswire/ -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a$60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharm...
2022-06-06 21:00
2363
Senhwa's Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC
TAIPEI and SAN DIEGO, June 6, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that it has received written approval from the Human Research Ethics Committ...
2022-06-06 21:00
1848
ASTRUM-005: Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022
SHANGHAI, June 6, 2022 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) announced that an international randomized phase 3 study (ASTRUM-005) of HANSIZHUANG (serplulimab), an anti-PD-1 mAb independently developed by Henlius, as first-line treatment for extensive-stage small-cell lung can...
2022-06-06 21:00
2108
CARsgen Therapeutics Presents Updated Data for CT041 Claudin18.2 CAR T-cells in Solid Tumors at ASCO 2022
SHANGHAI, June 6, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that at the 2022 American Society of Clinical Oncology (ASCO) Annual M...
2022-06-06 20:50
2725
Medison Pharma Announces Multi-Regional Partnership Agreement with argenx to Commercialize Efgartigimod Across Europe and Israel
PETACH TIKVAH, Israel, June 6, 2022 /PRNewswire/ -- Medison Pharma
2022-06-06 19:00
1809
NeuroAiD has shown favourable outcome in patients suffering from spinal cord injuries
* SATURN study aimed at assessing the safety and effects of a 6-month course of NeuroAiD (MLC601/MLC901) to augment functional and motor recovery after severe spinal cord injury (SCI). * NeuroAiD was safe as add-on treatment in patients with severe SCI. * One third of patients improved on AS...
2022-06-06 18:07
1578
CPHI China opens for international partnering after China rises in CPHI Index
The CPHI China Hosted Buyer Programme is empowering new partnering in China
SHANGHAI, June 6, 2022 /PRNewswire/ -- CPHI & P-MEC China
2022-06-06 16:51
4338
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...
2022-06-06 13:15
2405
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
* The National Medical Products Administration approved sugemalimab for the treatment of patients with unresectable stage III non-small cell lung cancer whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy * Sugemalimab became the first anti-PD-...
2022-06-06 12:23
1985
GILEAD SCIENCES APPOINTS DUSTIN HAINES AS NEW LEADER FOR ASIA 5 REGION
-- Mr Haines Brings a Strong Track Record of Global Commercial Successes and Corporate Leadership with a Career that Spans 20 Years in Pharmaceuticals -- -- He Joins Gilead's Asia 5 Team as the Company Celebrates 10 Years of Presence inAsia -- HONG KONG, June 6, 2022 /PRNewswire/ -- Gilead Scien...
2022-06-06 11:00
3507
OriCiro Announces Series B2 Financing to Advance Cell-Free DNA Technology for Innovative Therapeutics and Synthetic Biology
TOKYO, June 5, 2022 /PRNewswire/ -- OriCiro Genomics, a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapy and synthetic biology, today announced that it has closed Series B2 financing from Asahi Kasei Medical Co., Ltd. OriCiro has advanced its busine...
2022-06-06 10:09
1607
Research Updates on KN046 Presented at 2022 ASCO
SUZHOU, China, June 6, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that research updates from four clinical studies of KN046 (PD-L1/CTLA-4 bispecific antibody) presented as a poster or published online at the 2022 American Society of Clinical Oncology Annual Meeting (20...
2022-06-06 09:47
2497
Week's Top Stories
Most Reposted
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
[Picked up by 294 media titles]
2024-04-22 16:00
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
[Picked up by 291 media titles]
2024-04-22 06:00
Revenue Surpasses 50 Billion: BlueFocus Accelerates Towards the AI Native Era
[Picked up by 275 media titles]
2024-04-23 15:43
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 273 media titles]
2024-04-24 17:09
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
5328
Earth Day 2024: Angel Yeast Continues to Tackle Plastic Pollution Challenges With Bio-based Material Solutions
2024-04-22 16:00
4437
Trina Solar and PetroGreen Partner to Accelerate Philippine Solar Adoption with 117MW Supply Agreement
2024-04-22 06:00
4028
TCTM Filed 2023 Annual Report on Form 20-F
2024-04-20 05:48
3185
Dingdong Files Its Annual Report on Form 20-F
2024-04-20 05:00
2955